Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2268975 | 0.94 | OPRM1 (0.32) | OPRM1SIGMAR1CHRM4 | |
| SCHEMBL13274529 | 0.93 | SIGMAR1 (0.36) | OPRM1SIGMAR1 | |
| SCHEMBL13275361 | 0.93 | OPRM1 (0.32) | OPRM1SIGMAR1 | |
| SCHEMBL13275008 | 0.92 | OPRM1 (0.36) | OPRM1SIGMAR1CHRM4 | |
| SCHEMBL13274648 | 0.87 | HTR7 (0.35) | OPRM1SIGMAR1CHRM4 | |
| SCHEMBL13274528 | 0.87 | SIGMAR1 (0.36) | OPRM1SIGMAR1 | |
| SCHEMBL13275685 | 0.87 | OPRM1 (0.33) | OPRM1SIGMAR1 | |
| SCHEMBL13275357 | 0.86 | HDAC1 (0.32) | OPRM1SIGMAR1 | |
| SCHEMBL2365417 | 0.85 | CACNA2D1 (0.38) | — | |
| SCHEMBL13506662 | 0.85 | HTR7 (0.33) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | claimed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| WO-2011084402-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | OPRM1 2711/4885SIGMAR1 3491/4885CHRM4 4663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.